Essex Woodlands

Touchstone Health, a New York-based Medicare Advantage insurer. Touchstone offers a diverse portfolio of Medicare Advantage product options, including a choice of zero and low dollar co-pay plans with benefits including medical, pharmacy dental and mental health.

BioForm Medical, Inc., a medical aesthetics company, focuses on developing and commercializing products that are used by physicians to enhance a patient's appearance. Its core product is RADIESSE, an injectable dermal filler used to provide aesthetic improvement for patients. It markets its products through sales representatives and third party distributors to dermatologists, plastic surgeons, facial plastic surgeons, and other physicians performing cosmetic procedures in the United States, Europe, and internationally.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Since the company’s founding, Cord Blood Registry® (CBR®) has led the industry in technical innovations and provided families with access to current treatments and experimental stem cell therapies for conditions that have no cure. Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today. CBR has helped more than 300 families use their cord blood stem cells for established and experimental medical treatments, more than any other family cord blood bank. CBR’s goal is to expand the potential scope of newborn stem cell therapies that may be available to patients and their families. Cord Blood Registry is headquartered in San Bruno, California. CBR’s owned 80,000 square foot laboratory is located in Tucson, Arizona. Cord Blood Registry is a registered trademark of CBR Systems, Inc. CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification. CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality. A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future. CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today, including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of the stem cell units released by CBR have been used for experimental regenerative therapies – more than any other family cord blood bank in the world.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye.

Rinat, which means "happiness" in Hebrew, was formed in 2001 when Genentech, a leader in the development of therapeutic antibodies, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing antibody drugs for the treatment of diseases and disorders of the nervous system.

BreatheAmerica provides treatment facilities for patients suffering from breathing and other related allergic problems. BreatheAmerica is a company dedicated to improving how healthcare services are delivered to patients who suffer from chronic airway diseases - allergy, sinusitis, asthma, and other related diseases - with the goal of improving outcomes, reducing healthcare expenditures, and delivering an exceptional, differentiated patient experience. Joseph C. Hutts and Derril Reeves formed the company in Nashville, Tennesee in 2006.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

Yantai Beacon Medical Technology Co., Ltd. manufactures medical equipment, including, oxygen supply system. The company was founded in 2012 and is headquartered in Yantai, China. Yantai Beacon Medical Technology Co., Ltd. operates as a subsidiary of Bright Future (Hong Kong) Holding Ltd.

Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-U.S. markets. Bausch is the market leader in consumer visioncare in India and China, and the fourth- largest visioncare company by sales in the United States.

ATS Medical is a medical device manufacturer specializing in cardiovascular surgery products. ATS is a global company with product sales in more than 40 countries across the globe and superior product performance in more than 80,000 mechanical heart valves implanted to date. The ATS Open Pivot® Heart Valve utilizes a unique design specifically intended to offer advantages to the surgeon and improved quality of life to the patient. Instead of cavities in the hinge area, which is the case in all other bileaflet heart valves, The ATS Open Pivot® Heart Valve has open pivots. This enables the leaflets to pivot on smooth spheres that project gently into the bloodstream. The unique configuration eliminates cavities and stagnant areas where blood may collect and clot. For more information about The ATS Open Pivot® Heart Valve, please visit the expanded discussion for patients, physicians, or investors.

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

According to American Heart Association statistics, 20,000-40,000 patients in the United States would benefit from a heart transplant. The MicroMed DeBakey VAD®, jointly developed with Dr. Michael DeBakey, Dr. George Noon and the National Aeronautics and Space Administration (NASA), has the potential to keep many of these people alive until a donor heart becomes available. Weighing less than four ounces, the device is silent and is approximately 1/10 the size of other pulsatile products on the market. The MicroMed DeBakey VAD® is designed to be a lower-cost, less invasive alternative to the commercially available, larger ventricular assist devices (VADs).

MicroPort Scientific

WholePeople.com Inc., a multi-faceted e-commerce company in the "Whole Living" industry.

Corium International is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development.

Complete Genomics' high quality, affordable DNA sequencing enables commercial-scale research of the genetic mechanisms underlying drug responses and complex diseases. Complete Genomics combines innovative technology with a disruptive market approach that will revolutionize DNA sequencing.

Complete Genomics' high quality, affordable DNA sequencing enables commercial-scale research of the genetic mechanisms underlying drug responses and complex diseases. Complete Genomics combines innovative technology with a disruptive market approach that will revolutionize DNA sequencing.

Transforming Health Plan Customer Service

Ziopharm Oncology is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

Healthgrades, headquartered in Denver, Colorado, is the leading online resource for comprehensive information about physicians and hospitals. Today, more than one million people a day use the Healthgrades website to search, compare and connect with hospitals and physicians based on the most important factors when selecting a healthcare provider: experience, hospital quality and patient satisfaction. For more information about Healthgrades, visit http://www.healthgrades.com or download the Healthgrades iPhone app.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

BreatheAmerica provides treatment facilities for patients suffering from breathing and other related allergic problems. BreatheAmerica is a company dedicated to improving how healthcare services are delivered to patients who suffer from chronic airway diseases - allergy, sinusitis, asthma, and other related diseases - with the goal of improving outcomes, reducing healthcare expenditures, and delivering an exceptional, differentiated patient experience. Joseph C. Hutts and Derril Reeves formed the company in Nashville, Tennesee in 2006.

Nellix has developed an original device designed to address and expand the indication for the less invasive treatment of Abdominal Aortic Aneurysms (AAAs) and Thoratic Aortic Aneurysms (TAAs). Enabling the treatment of all aneurysms with a low profiles delivery system and innovative endograft, the Nellix device has the potential to double the market size for Endovascular Aneurysms Repair (EVAR), which exceeded $800M in 2008 with a 16% CAGR (Med Tech Insight).

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.

Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

Chroma Therapeutics Ltd. develops novel small molecule drugs based on chromatin biology and novel cell accumulation approaches for targeted cancer and inflammation treatments. Its products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for the treatment of cancer; and CHR-2845, a targeted solution for haemotological malignancies. The company was founded in 2000 and is based in Abingdon, United Kingdom.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

TissueTech is an innovative technology company that uses products derived from human amniotic and umbilical cord tissues. Its medical technology platform markets innovative amniotic and umbilical cord-based products, thereby enabling physicians to avail of enhanced regenerative healing technology in eye care, wound care, and orthopedics. Tissuetech was founded in 2001 and is headquartered in Miami, Florida.

Xenex is offering an effective approach to reducing the incidence of healthcare-associated infections. The Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). Xenex’s Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load often associated with an increased risk for HAIs. Since its commercial launch in June 2010, Xenex devices are now included in infection control protocols in almost three hundred hospitals throughout the U.S. Xenex was founded in 2009 and headquartered in San Antonio, Texas.

Prism Pharmaceuticals, Inc., an acute care pharmaceutical company, engages in developing and commercializing cardiovascular injectable products in the United States. Its products include NEXTERONE, an anti arrhythmic agent in the form of injectable amiodarone; and PM103, an intravenous formulation of clopidogrel bisulfate. The company was founded in 2004 and is based in King of Prussia, Pennsylvania.

Orthovita is a spine and orthopedic biosurgery company that manufactures and markets orthobiologic and biosurgery products. Its orthobiologics platform offers products for the fusion, regeneration, and fixation of human bones; and the biosurgery platform provides products for controlling intra-operative bleeding. Orthovita sells its products directly, as well as through non-stocking distributors and independent sales agents in the United States; and directly and through independent stocking distributors internationally. The company has strategic partnerships with Kensey Nash Corporation, Angiotech Pharmaceuticals, and Medafor. It was founded in 1992 and is based in Malvern, Pennsylvania.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

Spinal Concepts is a biotechnology company focused on spinal fixation products used in the treatment of spinal disorders, diseases, and injuries. The company was founded by Erin McGurk in 1996.

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for the right patient, at the right time, for the right price" so its customers can deliver the best patient care while reducing costs, and more easily meeting compliance demands. Only Millennium combines Just-In-Time Dispensing with electronic medication and treatment ordering, administration, documentation, and reporting. Millennium backs up the commitment with delivery timeliness and medication accuracy customer guarantees. Millennium is headquartered in Chicago, Illinois.

Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye.

AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

BENU, Inc. is an innovator in software technology for payroll, benefits and human resources. The company's newest platform, syncHR, reinvents the management of HR, benefits and payroll with its single application and single database. SyncHR's event-driven software provides real-time transactions, reduces administrative effort, increases data quality, and provides a seamless user experience.

United Orthopedic Group is a global orthopedic company with diverse operations all designed to provide outstanding service to our orthopedic physician customers. In addition, our manufacturing subsidiaries produce some of the highest quality non-invasive orthotic rehabilitation products available today to thousands of satisfied patients worldwide. We are a rapidly growing company with strong financial backing and an active acquisition program to add new partner companies to our team.

VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect's products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. The Vista Solution offers uninterrupted and continuous access to patient health through an online portal, monitoring 11 unique vital signs and providing predictive analytics. VitalPatch biosensor measures single-lead EKG, heart rate, heart rate variability, respiratory rate, body or skin temperature, body posture, fall detection, and activity [steps]. Together, Vista Solution 2.0 and the VitalPatch biosensor offer an elegant, best-in-class solution that increases patient mobility and comfort, provides oversight without additional caregiver burden, and enhances patient outcomes. Vista Solution also offers a predictive, comprehensive picture of patients through the integrated National Early Warning Score (NEWS) standard, providing clinicians' with the ability to optimize treatment for their patients.

Victory Pharma, Inc. is a specialty pharmaceutical company that acquires, markets and develops prescription pharmaceutical products that treat pain and related conditions. Victory markets these products to health care professionals through an experienced US commercial organization. They also develop novel products that effectively treat pain and minimize side effects commonly associated with widely-used pain therapeutics.

China Cord Blood Corporation (CCBC) is a provider of cord blood storage services in China. The Company is engaged in the provision of umbilical cord blood storage and ancillary services in its cord blood banks in the People’s Republic of China (PRC). As of March 31, 2013, the Company operated three cord blood banks in the Beijing municipality and Guangdong province and the Zhejiang province, the PRC. The Company provides cord blood storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public, provides matching services on such donated units and delivers matching units to patients in need of transplants.

Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologix's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.

Velcera is a specialty pharmaceutical company with a passion for assuring pets receive the medicines they need to support excellent overall health. At Velcera, they are dedicated to developing innovative, high-quality products for the pet health market. They comply with the highest standards of practice through all phases, from development to manufacturing to marketing.

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

Bioventus LLC develops and/or markets orthobiologic solutions for bone fusion and osteoarthritis. Its active healing therapies product line supports accelerated and more complete healing of bone fractures, and treats the chronic pain associated with osteoarthritis; and bone healing solutions work to enhance the body’s natural healing process. The company also provides injection therapies that treat osteoarthritic joints relieve pain and help bring mobility back to the patient; and surgical orthobiologics. Its products are available through a network of distributors. The company was incorporated in 2011 and is based in Durham, North Carolina. Bioventus LLC operates as a subsidiary of Bioventus Inc.

Chroma Therapeutics Ltd. develops novel small molecule drugs based on chromatin biology and novel cell accumulation approaches for targeted cancer and inflammation treatments. Its products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for the treatment of cancer; and CHR-2845, a targeted solution for haemotological malignancies. The company was founded in 2000 and is based in Abingdon, United Kingdom.

Cardiva Medical is a medical device company that’s focused on developing and commercializing innovative vascular closure technology designed to help the body heal itself following catheterization. The company’s products include VASCADE, a vascular closure system, and Catalyst II and Catalyst III, which are designed to aid manual compression. It was founded in 2002 and headquartered in Sunnyvale, California.

Healthcare Brands International (HBI) is a new company helping to turn innovative medical product technology into successful consumer brands.

Entellus Medical, Inc., doing business as Stryker ENT, designs, develops, and commercializes products for minimally invasive treatment of chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. The company offers XprESS ENT, a dilation system that delivers a combination of control and versatility for sinus and eustachian tube balloon dilation; XprESS LoProfile, a customizable fit patients anatomy for sinus and eustachian tube balloon dilation procedures; LATERA absorbable nasal implant, an implant that supports upper and lower lateral cartilage by anchoring maxilla to provide cantilever support; HD wireless camera; sterilization tray; and endoscopic imaging solutions. It also provides surgical instruments and tools, reinforced anesthesia needle, seekers and freers, sickle knife, forceps, suction and irrigation systems, shaver systems, sterilization tray, suction pumps, image-guided instruments, and nasal packing instruments. Entellus Medical, Inc. was founded in 2006 and is headquartered in Plymouth, Minnesota. As of February 28, 2018, Entellus Medical, Inc. operates as a subsidiary of Stryker Corporation.

Light Sciences Oncology, Inc. develops and manufactures talaporfin sodium for the treatment of tumors and other indications in patients. The company also offers drug activator, an LED based single use disposable device that provides a fixed light dose. Its drug is used for the treatment of patients with hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia and enlargement of the prostate. The company was founded in 1994 and is based in Bellevue, Washington.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

LifeCell Corporation develops and markets tissue repair products for use in reconstructive, urogynecologic, and orthopedic surgical procedures. The company’s products include Strattice Reconstructive Tissue Matrix and AlloDerm Regenerative Tissue Matrix for plastic, reconstructive, general surgical, burn, and periodontal procedures; Cymetra Regenerative Tissue Matrix, a particulate form of AlloDerm Tissue Matrix suitable for injection; and Repliform Regenerative Tissue Matrix for urogynecologic surgical procedures. It also offers GraftJacket for orthopedic surgical procedures; AlloCraft DBM for bone grafting procedures; and REVOLVE System that offers fat transfer processing in a range of aesthetic and reconstructive procedures. The company was founded in 1986 and is based in Branchburg, New Jersey. As of February 1, 2017, LifeCell Corporation operates as a subsidiary of Allergan plc.

Dow Pharmaceutical Sciences, Inc. engages in the development of topical drug products for pharmaceutical and biotechnology clients.

Rinat, which means "happiness" in Hebrew, was formed in 2001 when Genentech, a leader in the development of therapeutic antibodies, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing antibody drugs for the treatment of diseases and disorders of the nervous system.

Biotoscana Group (GBT) is a fast growing biopharmaceutical company in Latin America. The group was established through the merger of two leading specialty pharmaceutical companies, each with over 25 years experience in their respective markets: Biotoscana, founded in 1984, and United Medical, founded in 1987, sells leading brands GBT fields highly complex genetic disorders, rare diseases, oncology, hematology and specialized treatments, and has long-standing partnerships with leading global players in the pharmaceutical field.

IntegenX, Inc. designs, manufactures, and markets automation systems that enable reliable microsample preparation and analysis for the life sciences. It offers Apollo 100, a platform that allows the processing of DNA sequencing reactions; Apollo 200, an integrated sample preparation system for human DNA identification; microfluidics for DNA sequencing, molecular diagnostics, and human identification applications; and Apollo 324 system, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing. The company was formerly known as Microchip Biotechnologies, Inc. and changed its name to IntegenX, Inc. in March 2010. The company was incorporated in 2003 and is based in Pleasanton, California.

Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine. The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions. Metabolon was founded in 2000 and headquartered in Durham, North Carolina.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye.

Prolacta Bioscience Inc. develops and produces standardized human milk-based nutritional products for premature and critically ill infants in the neonatal intensive care unit (NICU). It offers human milk-based human milk fortifiers; human milk caloric fortifiers; standardized human milk; a ready-to-feed human milk-based premature infant formula; and solutions for early/trophic feeds and full feeds. The company was incorporated in 1999 and is headquartered in Duarte, California.

Accumetrics is a privately-held company that develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. Accumetrics, based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003.

Receptor Biologix develops receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases. The company is headquartered in Palo Alto, California.

QSpex Technologies, Inc., an optical service center, offers finished eyewear in the United States. It offers high impact, single vision, progressive, anti reflective, photochromic, and polar lenses. The company was founded in 2007 and is based in Alpharetta, Georgia. On June 8, 2020, QSpex Technologies, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

QSpex Technologies, Inc., an optical service center, offers finished eyewear in the United States. It offers high impact, single vision, progressive, anti reflective, photochromic, and polar lenses. The company was founded in 2007 and is based in Alpharetta, Georgia. On June 8, 2020, QSpex Technologies, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Ception Therapeutics is a biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. Ception was founded by experienced pharmaceutical executives in order to develop and commercialize therapeutics in areas of significant unmet medical need.

Suneva Medical, Inc. is a privately held medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It provides a novel and differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. The company’s flagship brand, Bellafill is the only dermal filler on the market with five-year safety and efficacy data, and the only dermal filler approved for the correction of facial acne scars. The Suneva Medical product portfolio focuses on compelling, differentiated products that deliver high patient satisfaction and represent a significant business opportunity to its practice partners. The company was founded in 2015 and headquartered in San Diego, California.

StrataGent Life Sciences, Inc. is a specialty drug therapy company developing painless, non-invasive versions of therapies that would otherwise be injected. Its products are based on its proprietary microjet technology, which delivers large and small therapeutic molecules without a device penetrating into or through the skin. In May of 2004, StrataGent received a $2 million award from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology to support the development of the StrataGent microjet technology.

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Entellus Medical, Inc., doing business as Stryker ENT, designs, develops, and commercializes products for minimally invasive treatment of chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. The company offers XprESS ENT, a dilation system that delivers a combination of control and versatility for sinus and eustachian tube balloon dilation; XprESS LoProfile, a customizable fit patients anatomy for sinus and eustachian tube balloon dilation procedures; LATERA absorbable nasal implant, an implant that supports upper and lower lateral cartilage by anchoring maxilla to provide cantilever support; HD wireless camera; sterilization tray; and endoscopic imaging solutions. It also provides surgical instruments and tools, reinforced anesthesia needle, seekers and freers, sickle knife, forceps, suction and irrigation systems, shaver systems, sterilization tray, suction pumps, image-guided instruments, and nasal packing instruments. Entellus Medical, Inc. was founded in 2006 and is headquartered in Plymouth, Minnesota. As of February 28, 2018, Entellus Medical, Inc. operates as a subsidiary of Stryker Corporation.

iKnowMed, a privately held healthcare company located in Berkeley, California, is building the world's leading clinical infomediary, a trusted repository and resource for mission-critical, real-time, point-of-care information. Using patented web-based programs iKnowMed uniquely captures, analyzes, and displays patient treatment information at the point-of-care, enabling clinicians to advance the standard of care during medicine's moments of truth. In addition, iKnowMed's electronic infomediary provides unprecedented opportunities for physicians, patients, and pharmaceutical organizations to interact with and benefit from one another.

QSpex Technologies, Inc., an optical service center, offers finished eyewear in the United States. It offers high impact, single vision, progressive, anti reflective, photochromic, and polar lenses. The company was founded in 2007 and is based in Alpharetta, Georgia. On June 8, 2020, QSpex Technologies, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.